Evgen Pharma Share Discussion Threads

[moneymunch] 16/5/2021 20:17

A great reminder from parkez on LSE...the multi-billion dollar Chinese Raybow, bought PharmAgra in 2019, who Evgen have world wide exclusive rights to SFX-01 and its analogues, and Raybow have just invested $15m ( 22/3/21) to expand PharmAgra manufacturing capacity in the US.....all bodes well. Gl :-)

[moneymunch] 16/5/2021 12:16

A risk/reward firmly in our favour imho....although no guarantees of course, but a complete game changer if Prof Chlamers reports positive efficacy data which would very likely see SFX-01 as prime candidate for Boris's home pill target and perhaps he's already put a forward order in for a 100 million doses or so.....can you imagine??? Gla ;-))))

Evgen Pharma plc, of Cheshire, U.K., said a preprint publication from Johns Hopkins University demonstrates that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by several variants of the SARS-CoV-2 virus and another coronavirus. Data showed that the inhibition of SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are pretreated with sulforaphane and when sulforaphane is administered 24 hours after viral inoculation. The work also shows that sulforaphane acts synergistically with the antiviral drug remdesivir (Gilead Sciences Inc.). The authors further established that the effects of sulforaphane, administered orally, were observed in vivo in a mouse model infected with the SARS-CoV-2 virus, where reduction in both viral load and lung pathology were observed.

[mikro1] 15/5/2021 23:46

I'm still holding.. its a complete gamble but at this market cap I like the odds!

[bocker01] 14/5/2021 19:43

Dead right!

[moneymunch] 14/5/2021 16:42

Lol, yep it's been a bit of a chore, but hopefully those that haven't will be very well rewarded very soon.....fingers firmly crossed....Gl ;-)

[riggerbeautz] 14/5/2021 16:19

Feels like a few have snuck out the back door, bored more than anything.

[moneymunch] 14/5/2021 15:51

Perfectly poised for news imho ( good or bad )....although the chart almost looks like a carbon copy of SNG's last year which was also on the slide, just before their stellar rise.....Tick Tock .....C'mon Prof Chalmers, Huw and Co....time's UP...next week please!!! ;-)))

[moneymunch] 13/5/2021 17:30

Exploratory objectives (All sites)


Biofire analysis of nasal swab or sputum sample


Subanalysis of outcomes according to the causative pathogen


Exploratory objectives (TAYSIDE ONLY)


Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells


Neutrophil functional studies in isolated cells


Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood

[moneymunch] 13/5/2021 16:46

Snap indeed muddy, and yet more weight to SFX-01's chances....i wonder what "drug treatment" they have in mind??? Gl ;-)


"The project will explore whether abnormally high activation of neutrophils is responsible for long term damage to the endothelium and small blood vessels in Covid-19 patients.

It will also examine whether reducing activation of neutrophils with drug treatment reduces damage to the endothelium and improves the function of the blood vessels."

........................

"Sulforaphane decreases neutrophil hyperactivity by reducing intracellular oxidative stress"

[muddy_40] 13/5/2021 09:32

Snap Moneymunch- same but different..lol

[moneymunch] 13/5/2021 09:22

A very interesting research project announced today by University of Dundee on their focus on the roll of of neutrophils and the harmful inflammation effects of Covid-19, which must add weight to SFX-01's anti-inflammatory properties and interestingly enough "Neutrophil functional studies in isolated cells" are part of the Exploratory objectives of SFX-01 Covid/Ards trial at University of Dundee, and so the timing could be viewed as encouraging??? Gla :-)


Project to investigate blood vessel damage in Covid-19 patients

Published on 12 May 2021



Harmful effects of Covid-19 are excessively high in people who have pre-existing diseases of the heart and blood vessels. Covid-19 can also cause ‘new’ damage to the heart and blood vessels in people who have no pre-existing disease.

The lining of blood vessels, called endothelium, acts as a barrier and first point of contact for the virus. From recent research studies, there is evidence that the virus causes damage to the endothelium which, in turn, leads to disease of the heart and blood vessels, particularly the very small blood vessels, called microvessels.

It is thought that inflammation in the body caused by Covid-19 might be responsible for some of these harmful effects. Inflammation is a protective mechanism activated by the body’s immune system to fight infection, remove harmful toxins and help in the healing process. However, inflammation can also have detrimental effects on the human body, especially when it does not resolve and becomes persistent, as in Covid-19.

The project will be led by Faisel Khan, Professor of Cardiovascular Sciences at Dundee’s School of Medicine. Professor Khan and his team believe that abnormal activation of a type of white blood cell, called the neutrophil, important in the body’s immune response, might be linked with Covid-19 and cause damage to the blood vessels.

Professor Khan said, “As Covid-19 is still a relatively new disease, we are still trying to understand how it affects the body. We know that people with pre-existing cardiovascular conditions are more likely to suffer from serious complications, and that Covid-19 itself can damage the heart and blood vessels.

“With this project, we hope to be able to better understand why and how Covid-19 damages the cardiovascular system, and hope to find new ways to prevent or reduce that damage, improving outcomes and quality of life for patients.

“We are very grateful to Heart Research UK for supporting this exciting research.”

Recent research has shown that drug treatment to reduce the abnormal activation of neutrophils can improve the symptoms of patients who have bronchiectasis, a lung disease caused by inflammation.

The project will explore whether abnormally high activation of neutrophils is responsible for long term damage to the endothelium and small blood vessels in Covid-19 patients. It will also examine whether reducing activation of neutrophils with drug treatment reduces damage to the endothelium and improves the function of the blood vessels.

The team will assess the function of the small blood vessels over 12 months in patients who have had Covid-19 to see if this is abnormal compared with healthy people who have not had the disease. They will apply small amounts of chemicals to the skin and use a laser machine, which measures blood flow in the microvessels, to assess how well the blood vessels are working. They will also take blood samples to measure the activation of neutrophils and see if high levels of activation are linked to blood vessel damage.

They will also use these methods in patients who have been hospitalised with Covid-19 to compare the effects of drug treatment versus placebo on the activation of neutrophils and function of the blood vessels.

The study will show whether increased activation of neutrophils contributes to development of long-term disease of the blood vessels in Covid-19 patients and whether reducing their activation has beneficial effects. Targeting neutrophils in this way could be an important treatment option for reducing blood vessel and heart complications in people who have Covid-19.

[moneymunch] 13/5/2021 07:10

Yep, although as well as SFX-01 Prof Chalmers will have other areas of research on Covid, but if SFX-01 wasn't looking good then you would expect a transfer of staff rather than the recruitment of more if the trial was to be discontinued???? Gl ;-)

James D Chalmers
@ProfJDChalmers
·
10 May
Just two days left to apply for our technician post
Who wouldn't want to work on epithelial biology in lung disease?

Come and join us!



An opportunity has arisen for a research technician to support our internationally leading Lung Infection laboratory at the University of Dundee. The group studies a range of lung infections including COPD, bronchiectasis and COVID-19.

You will be expected to provide high quality technical assistance to Professor Chalmers, Dr Shoemark and the other members of the research team. Core tasks will include processing biological samples, culture of airway epithelial cells at air liquid interface, cell culture experiments, microscopy and generation of experimental data using methods such as ELISA.

You will support the principal investigators, post-docs and PhD students as part of a multidisciplinary team, performing laboratory research to a high standard, organising study data and supervising undergraduates. You will work collaboratively with team members to support multiple ongoing research studies with a focus on the role of motile cilia in chronic lung disease.

[dlg3] 12/5/2021 23:34

The fact they actively seeking a technician to work on Covid19 at Dundee shows that they intend to continue, so the results must be positive or covid19 would be omitted from the job ad....

[moneymunch] 12/5/2021 10:29

Ditto on the the approvals muddy, maybe results so compelling they're already under Peer Review in line for Boris's home pill Autumn target. :')))

[muddy_40] 12/5/2021 10:24

MM. I reckon that also. Longer it takes the more chance it is good, if it has shown good efficacy why bother with placebo, maybe forward trials will be alone and trials with other treatments. So maybe getting approvals for next step. All speculation of course.

Must be news soon

[moneymunch] 12/5/2021 10:17

No news is good news I reckon, and I'm sure Huw would want any bad news out of the way by now so he could get on with updating the market on the rest of the pipeline, and Prof Chalmers appears to be an incredibly busy bloke , and so a comprehensive and detailed positive efficacy assessment presumably will take a lot longer than a negative one...Gla :-)

[pdt] 12/5/2021 10:14

Interesting new article which supports EVG approach;

"How Severe COVID-19 Can Tragically Lead to Lung Failure and Death"



The article reviewed the results from autopsy studies from the lungs of COVID patients. Among the findings were high levels of IL-1β, large number of fibroblasts leading to pulmonary fibrosis and alveoli unable to repair themselves.

The recent John Hopkins study results demonstrated Sulforaphane reduced IL-1β and TGF-beta implicated in Fibroblast production.

Another paper suggested that inhibition of NF-Kb would be beneficial to the alveoli type II cells mentioned above, Sulforaphane is again useful in that area.

"Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory"

[moneymunch] 12/5/2021 09:58

Lol...Tick Tock...:-)

[moneymunch] 09/5/2021 21:21

Boris is making an announcement on easing lockdown measures tomorrow at 5pm...I wonder if he'll have news on any progress made on his home pill Autumn target???...news from Prof Chalmers must be close...can you imagine if SFX-01 gets a mention. :-)

[moneymunch] 09/5/2021 18:03

Steroids are heavy duty with heavy duty side effects, and although effective in some serious cases of Covid, certainly won't be the home pill target for all and sundry to pop every other week that Boris had mind. :-)

[bumpa33] 09/5/2021 17:55

looks like possibly careless dosing of steroids in diabetics? Even so, horrific.

[mesquida] 09/5/2021 17:28

And now steroids are being criticized as a treatment for Covid patints....see today's BBC report on the black mould that is proving fatal to recovering Covid patients.